Philippine-based digital health startup GoRocky has secured $2 million in fresh funding, while Thailand’s GetLinks has acquired edtech firm Xccelerate.
PH digital health startup GoRocky secures $2m funding
Philippine-based digital health startup GoRocky has announced raising $2 million in a seed funding round co-anchored by Singapore’s Integra Partners and local venture firm Kaya Founders.
The startup, founded in 2022, declared it will utilize the fresh funds to expand from men’s health into chronic-care services, covering obesity, diabetes, and hypertension.
GoRocky launched by offering discreet care for erectile dysfunction and hair loss and states it has supported more than 30,000 patients. The startup declared the new funding will assist build a broader platform that links patients with licensed doctors, pharmacies, and diagnostic providers.
“Millions of Filipinos are living with conditions they can’t easily treat, not becautilize they don’t care, but becautilize the system builds it too hard,” declared co-founder and chief commercial officer Joaqui Palaña.
GoRocky declared all patients undergo medical consultations and diagnostics before treatment.
Thailand’s GetLinks acquires Xccelerate
Thailand-based talent platform GetLinks has acquired Xccelerate, an education technology firm offering digital skills training, according to an announcement.
Financial terms of the deal were not disclosed. The acquisition pairs GetLinks’ AI-driven job-matching and career tools with Xccelerate’s workforce programs in artificial ininformigence, huge data, cybersecurity, and UX/UI design, creating a combined offering for employers and job seekers across the region.
The companies declared the integration will expand access to technical training, widen the talent pool available to hiring managers and improve placement outcomes.
Post-acquisition, the platforms will coordinate on curriculum updates and credentials, while offering employers tarobtained hiring campaigns and candidates’ skills-based job recommconcludeations.
















Leave a Reply